Evaluation of Satisfaction in Patients Receiving PegIntron Pen/Rebetol for Hepatitis C (Study P04067) (SATISFACTION)

Merck Sharp & Dohme (MSD)

Status: Completed

Conditions: Hepatitis C, Chronic

Treatments: Biological: Peginterferon alfa-2b (SCH 54031); Drug: Ribavirin (SCH 18908)

Study type: Observational

Funder types: Industry

Identifiers

NCT00727259

P04067

Details and patient eligibility

About

The current gold standard for treatment of chronic hepatitis C (CHC) patients is with pegylated interferon plus ribavirin. Drug administration accuracy and ease of use will definitely determine treatment effectiveness. This is the idea behind the development and usage of the PegPen. The goal of this study is to determine the satisfaction grade with this novel device.

Full description

Enrollment of patients will occur in a sequential order of treatment initiation.

Enrollment: 1,995 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients with hepatitis C

Exclusion criteria

• According to the products' labeling.

Trial design

1,995 participants in 1 patient group

Patients with chronic hepatitis C

Description:

Adult patients with chronic hepatitis C treated with PegIntron pen/Rebetol.

Treatment:

Drug: Ribavirin (SCH 18908)

Biological: Peginterferon alfa-2b (SCH 54031)